Insiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone
TipRanks (Sat, 11-Apr 9:01 AM ET)
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Clene to Present at the Emerging Growth Conference
Globe Newswire (Thu, 19-Feb 8:30 AM ET)
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
Globe Newswire (Wed, 21-Jan 7:00 AM ET)
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
Globe Newswire (Tue, 20-Jan 7:00 AM ET)
Statistically Significant ALS Biomarker Results Boost CNM-Au8’s Accelerated Approval Prospects
Market Chameleon (Wed, 3-Dec 3:58 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of April 15, 2026, CLNN stock price climbed to $6.70 with 5,185 million shares trading.
CLNN has a beta of 2.23, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.06 to the broad based SPY ETF.
CLNN has a market cap of $78.91 million. This is considered a Micro Cap stock.
Last quarter Clene reported $77,000 in Revenue and -$.88 earnings per share. This beat revenue expectation by $48,500 and missed earnings estimates by -$.33.
In the last 3 years, CLNN traded as high as $21.80 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.
CLNN has outperformed the market in the last year with a price return of +117.5% while the SPY ETF gained +30.5%. CLNN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.9% and +35.9%, respectively, while the SPY returned +1.1% and +7.1%, respectively.
CLNN support price is $6.08 and resistance is $7.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.